Please upgrade your browser.
AVEO Pharmaceuticals Human Response Platform and Proprietary Mouse Models Featured in Nature Reviews Cancer
Tivozanib is currently being investigated in a global, randomized Phase 3 clinical trial called TIVO-1 comparing tivozanib to sorafenib in advanced kidney cancer, as well as additional clinical studies in other solid tumor types.
Laparo-endoscopic single-site (LESS) radical nephrectomy with renal vein thrombectomy: initial report
By combining trocar sites and extraction incision, Laparo-endoscopic Single-site Surgery (LESS) may provide less morbidity than traditional laparoscopy. Concerns continue about LESS for locally advanced tumors. We present our experience with LESS-radical nephrectomy with renal vein thrombectomy (LESS-RN-RVT).
MicroRNA profiling of clear cell renal cell carcinoma by whole-genome small RNA deep sequencing of paired frozen and formalin-fixed, paraffin-embedded tissue specimens
Renal cell carcinoma (RCC) is one of the leading causes of cancer mortality. Characterization of microRNA (miRNA) expression of RCC will help disclose new pathogenic pathways in tumourigenesis and progression and may lead to the development of molecular biomarkers and target-specific therapies for diagnosis, prognostication and treatment.
Interrupting blood flow for more than 20 to 25 minutes during kidney cancer surgery leads to a greater risk for patients developing chronic kidney disease, according to a new study.
The Pharmacor 2010 findings from the topic entitled Renal Cell Carcinoma reveal that significant uptake of the angiogenesis inhibitor Votrient/Patorma will be driven by its use in treating advanced renal cell carcinoma, particularly in the first-line setting. As a result, Votrient/Patorma will become the market leader and will garner sales of nearly $630 million in 2019 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
McDonald did it for his father, Jack, who died on June 14 after an eight-month ordeal with liver and kidney cancer.
This is an open-label, multi-center study to evaluate the safety of RAD001 in Chinese patients with metastatic renal cell cancer who are intolerant of or have progressed despite treatment with vascular endothelial growth factor (VEGF)-targeted therapies.
Psoriatic Skin Lesions Induced by Tumor Necrosis Factor Antagonist Therapy: Clinical Features and Possible Immunopathogenesis
TNF antagonist induced psoriasis is a welldescribed adverse event without any known predisposing risk factors.
The impact of family history on pathological and clinical outcomes in non-syndromic clear cell renal cell carcinoma
Patients with a family history of ccRCC have pathological and clinical outcomes similar to patients with sporadic ccRCC.
Carbonic anhydrase IX is a promising target for improving diagnosis, prognosis, and therapy of renal cell carcinoma (RCC) patients.
|Powered by NeonCRM|